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ABSTRAK
Midazolam adalah salah satu ubat yang paling biasa digunakan sebagai ubat pelali 
di Jabatan Kecemasan (ED). Ini adalah satu kajian retrospektif yang dijalankan ke 
atas 380 pesakit dari Disember 2012 hingga Mei 2014 di ED, Pusat Perubatan 
Universiti Kebangsaan Malaysia (PPUKM). Objektifnya adalah untuk mendapatkan 
kekerapan kesan sampingan dan korelasi kepada pelbagai faktor iaitu sosio-
demografi, kumpulan umur dan penyakit-penyakit utama. Daripada 380 pesakit, 
35 pesakit mempunyai kesan sampingan (20 pesakit dengan midazolam sahaja, 
15 pesakit dengan kombinasi ubat-ubatan). Umur purata adalah 42 tahun dan dos 
purata midazolam adalah 3.5mg. Ubat lain yang paling biasa di gabung adalah 
fentanyl. Kadar komplikasi keseluruhan midazolam adalah 5.3%. Kesan sampingan 
yang paling biasa yang dicatatkan adalah somnolen (1.6%). Kesan sampingan yang 
lain adalah reaksi alergi kulit (1.1%), muntah (0.8%), sakit kepala (0.8%) dan tekanan 
darah rendah (0.5%). Tidak ada hubungan yang signifikan antara faktor-faktor 
sosio-demografi dan kombinasi ubat-ubatan dengan kesan sampingan midazolam 
pada pesakit. Kesimpulan daripada kajian ini ialah midazolam adalah dadah yang 
sangat selamat kerana ia tiada kesan sampingan yang mengancam nyawa. Terdapat 
kemungkinan bahawa kesan-kesan sampingan direkodkan boleh disebabkan oleh 
faktor-faktor lain seperti kecederaan atau penyakit  dan kombinasi dengan ubat-
ubatan lain.
Kata kunci:  Midazolam, somnolen, tekanan darah rendah, reaksi alahan kulit, sakit 
kepala, muntah 
ABSTRACT
Midazolam is one of the most commonly used drugs for sedation in Emergency 
Department (ED). This was a retrospective study conducted on 380 patients from 
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Procedural sedation is commonly used 
for outpatient medical procedures and 
done by non-anesthesiology physicians 
(Knape et al. 2007).
 The use of midazolam in the ED 
is unique in terms that the location 
possess different issues and risks to 
the physician. Among issues that is 
different to normal outpatient clinic is 
the occurrence which is unpredictable, 
the timing is time dependent and 
sometimes emergent, gastric state is 
variable (either fasted or not). Patients 
are unselected and may have underlying 
systemic disease (Godwin et al. 2005).
Hence, even though the adverse effects 
of midazolam was extensively studied 
in various clinical locations, the data 
for midazolam use in ED especially 
throughout Malaysia, is still lacking. 
  Adverse reactions from midazolam 
use include urinary retention, nausea, 
vomiting and excessive somnolence 
December 2012 to May 2014 in ED of Universiti Kebangsaan Malaysia Medical 
Centre (UKMMC). The objective was to elicit the frequency of side effects and 
correlation to various factors i.e. socio-demography, co-morbidities, age groups 
and underlying illnesses. Out of 380 patients, 35 patients experienced side effects 
(20 patients with midazolam alone, 15 patients with combination of drugs). The 
average age was 42 years and the average dose of midazolam was 3.5mg. The 
most common other drug combined was fentanyl. The overall complication rate 
for midazolam was 5.3%. The most common side effect recorded was excessive 
somnolence (1.6%). Other side effects included local skin reactions (1.1%), vomiting 
(0.8%), headache (0.8%) and hypotension (0.5%). There was no significant 
association between the socio-demographic factors and drugs combination with 
the side effects of midazolam on patients. It was concluded that midazolam was a 
safe drug due to absence of any life-threatening side effects. There are possibilities 
that most side effects recorded could be caused by other comfounding factors e.g. 
underlying injuries or disease and combination with other drugs.
Keywords: Midazolam, excessive somnolence, hypotension, local skin reaction, 
headache, vomit
INTRODUCTION
Midazolam is a water-soluble 
imidazobenzodiazepine derivative 
which is commonly used for sedation 
in the Emergency Department (ED) 
(Ramoska et al. 1991). The reason 
attributed to this is that it possesses 
potent anxiolytic, amnesic, hypnotic 
and sedative properties (Khanderia 
& Pandit 1987; Olkkola & Ahonen 
2008; Barash et al. 2009). The present 
study was to assess the incidence of 
adverse effects following intravenous 
midazolam given to patients in the 
ED. Reasons for sedation in the ED are 
chemical restrains of violent patients 
and procedural sedation and analgesia 
(PSA). PSA is the administration of 
sedatives to induce a depressed level 
of consciousness while maintaining 
cardio respiratory functions. This is 
done so that a medical procedure 
can be done (Godwin et al. 2005). 
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(Ramoska et al. 1991). Few serious 
incidents were reported with the 
administration of midazolam. In 1989, 
Roche Laboratories received 74 deaths 
reports with regard to midazolam use. 
Majority of the midazolam deaths were 
used as an adjunctive agent, which 
complicated with respiratory arrest. 
Overdosage, co-morbidities, old age 
and use in adjunct to other central 
nervous depressants are the main 
factors which lead to this mortality 
(Ramoska et al. 1991). 
MATERIALS AND METHODS
This was a retrospective study 
conducted on 380 patients who 
received intravenous midazolam in ED, 
UKMMC from December 2012 to May 
2014. Data collection commenced 
following receiving approval from 
UKMMC’S Ethical Committee. 
Registration numbers of the patients 
that fulfilled all inclusion criteria were 
collected from the controlled drugs 
record. Data was then collected from 
the Records Department. Data was 
documented in the data collection 
sheet and then analyzed using 
Statistical Package for Social Sciences 
(SPSS) Windows Version 20.0. Chi-
square test was used to analyze the 
association between the side effects of 
midazolam and factors studied. P value 
of <0.05 was described as statistically 
significant. 
 The main objective of the was to 
look into the incidence of adverse 
effects after intravenous midazolam 
administration in the ED.
 We also aimed to (i) determine the 
association between adverse effects 
of intravenous midazolam with socio-
demographic factors (ii) determine the 
association between adverse effects 
of intravenous midazolam with co-
morbidities and underlying illnesses (iii) 
compare adverse effects of midazolam 
when used alone with certain drug 
combinations (iv) determine the 
occurrence of life threatening adverse 
effects with intravenous midazolam 
administration.
SAMPLE SIZE CALCULATION
Formula by Cochran (1963),
n = x p (1 – p)
95% confidence level 
z = degree of confidence value (1.96 for 
95% confidence level) = 1.96
∆ = Error of margin 0.005 (0.5%)
p = expected prevalence
Based on an earlier study (Khanderia & 
Pandit 1987), the overall complication 
of side effects midazolam was 1% and 
the error of margin 0.015
n =  ( 1.96 )2  x 0.01(1 – 0.01)
       0.01 
= 380 patients (rounded to zero decimal 
points)
INCLUSION CRITERIA
Patients administrated intravenous 
midazolam in the ED, UKMMC from 
December 2012 to May 2014. 
EXCLUSION CRITERIA 
1.  Midazolam indicated for rapid 
sequence intubation (RSI) – due 
to its use as an induction agent, 
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not for procedural sedation and 
analgesia or chemical restrain of 
violent patients.
2.  Patient transferred to another 
hospital.
3.  Midazolam dependence.
RESULTS
This study involved a total of 380 
patients. The mean age was 42 
years with minimum of one year and 
maximum of 108 years. Majority were 
males (64.7%) and Malays (43.2%) were 
the highest population involved. Other 
populations included Chinese (39.2%), 
Indians (9.2%) and others (8.4%). 
According to races, Chinese (5.0%) 
was the most population associated 
with side effects of midazolam use 
while Malays (43.2%) were the highest 
population involved in the midazolam 
use (Jabatan Perangkaan Malaysia 2010) 
(Table 1). For patients aged 40 years and 
below, the adverse effects were 6.3% 
(13 out of 206 patients), whereas for age 
41-60 years, it was 11.5% (10 out of 87 
patients) and 61-80 years were 10.6% 
(7 out of 66 patients). Incidence of side 
effects in patients more than 80 years is 
significantly higher (38/1%), (8 out of 21 
patients (Table 1).
 Two hundred and thirty nine (63%) 
patients had midazolam combined 
with other drugs.  The drugs combined 
with midazolam were fentanyl (28.7%), 
morphine (16.6%), haloperidol (8.7%), 
propofol (6.1%), ketamine (2.1%) and 
diazepam (0.8%). Overall number 
of patients who suffered adverse 
effects recorded with midazolam 
administration was 35 (9.2%). 
Table 1: Association of socio-demographic factors with side effects of Midazolam use  
Group
Total n (%) p valueSide Effects 
n (%)
No Side Effects 
n (%)
Age (years)
1-20  4 (1.1)  59 (15.5)  63 (16.6)  0.48
21-40  9 (2.4)  134 (35.3)  143 (37.6)
41-60  10 (2.6)  77 (20.3)  87 (22.9)
61-80  7 (1.8)  59 (15.5)  66 (17.4)
>80 8 (0.8) 18 (4.7) 21 (5.5)
Gender
Male  18 (4.7)  228 (60.0)  246 (64.7) 0.20
Female 15 (3.9) 119 (31.3) 134 (35.3)
Race
Malay  12 (3.2)  152 (40.0)  164 (43.2)  0.10
Chinese  19 (5.0)  130 (34.2)  149 (39.2)
Indians  1 (0.3) 34 (8.9)  35 (9.2)
Others 1 (0.3) 31 (8.2) 32 (8.4)
p value age 0.48; gender 1.20; race 0.10, Chi-Square test
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Breakdown of overall adverse effects 
were excessive somnolence 10 (2.6%) 
patients, hypotension 7 (1.8%) patients, 
drug hypersensitivity reaction 6 (1.6%) 
patients, headache 5 (1.3%) patients and 
vomiting 4 (1.1%) patients and 3 (0.8%) 
patients had tachypnea, increased 
blood pressure and ECG changes.
 Midazolam and fentanyl were 
the mostly combined drugs (47.4%) 
and it had the highest combination 
(4.2%) with side effects of midazolam 
use. Six patients who received this 
combination of drugs had transient 
hypotension. However, there was no 
significant association with p value of 
0.38. Combination of midazolam with 
propofol or ketamine recorded no side 
effects. Table 2 showed the association 
of interaction of midazolam with one 
specific drugs and side effects whereas 
Table 3 showed the association of 
interaction of midazolam with various 
drugs combination and side effects. 
The total side effects with midazolam 
used alone was 20 (5%) compared to 
15 (3.9%).
 Among the comorbidities, 
hypertension (1.6%) was the highest 
comorbidity associated with 
midazolam use followed by asthma 
and diabetes mellitus which was 0.5% 
respectively. Other comorbidities 
were tabulated (Table 4). There were 
seven indications of midazolam and 
sedation (58.9%) was the highest 
Table 2: Association of interaction of midazolam with one specific drugs and side effects 
Drugs
Group
Total n (%) P valueSide Effects 
n (%)
No Side Effects
 n (%)
Midazolam + Fentanyl 5 (4.2) 51 (43.2) 56 (47.4) 0.38
Midazolam + Propofol 0 (0.0) 8 (6.8) 8 (6.8) 0.43
Midazolam + Ketamine 0 (0.0) 6 (5.1) 6 (5.1) 0.50
Midazolam + Morphine 1 (0.8) 19 (16.1) 20 (16.9) 0.73
Midazolam + Haloperidol 2 (1.7) 24 (20.3) 26 (22.0) 0.83
Midazolam + Diazepam 0 (0.0) 2 (1.7) 2 (1.7) 0.70
p value Midazolam + Fentanyl 0.38; Propofol 0.43; Ketamin 0.50; Morphine 0.73’ Haloperidol 0.83; 
Diazepam 0.70, Chi-Square test
Table 3: Association of interaction of midazolam with various drugs combination and 
side effects 
Side effects Midazolam only (N=20)n (%)
Midazolam and others (N=15)
n (%) p value
Local skin reaction 4 (1.1) 2 (0.5) 0.51
Hypotension 2 (0.5) 5 (1.3) 0.18
Excessive somnolence 6 (1.6) 4 (1.1) 0.67
Vomit 3 (0.8) 1 (0.3) 0.38
Headache 3 (0.8) 2 (0.5) 0.77
Others 2 (0.5) 1 (0.3) NA
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indication of midazolam to be used. 
Other indications were orthopaedic 
procedures (17.9%), psychotic 
disturbances (10.5%), anticonvulsants 
(9.5%), anxiety (2.4%) and chest tube 
insertion (0.8%). Midazolam was given 
intravenously with dosage varying from 
1.0 mg to 10.0 mg and the mean dose 
was 3.5 mg.
DISCUSSION
We managed to gather a sample size 
of 380. The study population ethnicity 
breakdown comprised Malays-43.2%, 
Chinese-39.2%, Indians-9.2% and 
others-8.4% and it did not resemble 
the ethnicity of the Cheras region. This 
region has a population breakdown 
of 25.4% (3,101) Malays, 40% (4,910) 
Chinese, 7.6% (932) Indians and others 
(non-malay bumiputra, Malaysian 
nationals and foreigners) 27% (Jabatan 
Perangkaan Malaysia 2010). It resembles 
the population of Kuala Lumpur as 
a whole, which has a breakdown 
of 40.6% (644,406) Malays, 39.1% 
(621,805) Chinese and 9.3% (148,300) 
Indians. Although Chinese (5.0%) were 
more associated with side effects, there 
was no significant association between 
races and side effects of midazolam use 
(p=0.1).  The highest gender associated 
with side effects was males (4.7%), and it 
correlated to the majority male patients 
who had midazolam administered. The 
correlation between gender and side 
effects was not significant (p=0.2) 
 Out of total 35 patients who 
experienced side effects, 13 patients 
(37% out of total with side effects) were 
below 40 years. Ten patients were 
between the age of 40 to 60 years and 
the rest (12 patients) were above 60 
years old. There was no significance in 
the relation of age and adverse effects, 
as the distribution could be seen as 
nearly equal. However, when used 
in the extreme ages (above 80 years), 
a higher proportion of adverse effects 
were observed (38.1% - 8 out of 21 
patients) as shown in Table 1.  Elderly 
patients receiving midazolam 0.06 mg 
kg-1 showed significant reductions in 
mean blood pressure, respiratory rate 
and SpO2 (Sun et al. 2008). Elderly 
patients (>70 years) previously on 
diazepam in particular has a higher 
propensity of falls compared to other 
benzodiazepam users (Ballokova et 
al. 2014). There was also an increase 
in fracture risk with short term 
benzodiazepine usage, (RR = 1.21; 95 % 
CI, 1.13–1.30) with a weak significance. 
Table 4: Comorbidities with side effects of Midazolam use
Comorbidities
n (%)
Group
TotalSide Effects 
n (%)
No Side Effects 
n (%)
Hypertension 6 (1.6) 61 (16.1) 67 (17.7)
Asthma 2 (0.5) 13 (3.4) 15 (3.9)
Diabetes Mellitus 2 (0.5) 36 (9.5) 48 (10.0)
Schizophrenia 0 (0.0) 11 (2.9) 11 (2.9)
Cerebrovascular Accident (CVA) 1 (0.3) 13 (3.4) 14 (3.7)
8Med & Health 2016;11(1): 2-10 Nik Muhammad N.A. et al.
This was also observed in the elderly 
age group (>65 years) (Xing et al. 2013). 
Extra caution should be practiced when 
administering benzodiazepine among 
elderly, especially at extreme ages 
(>80), as they are more susceptible to 
adverse effects. However, in the young 
(pediatric and adolescent), significant 
adverse effects are rare. A review by 
Papineni et al. (2014) showed that 
after oral administration of midazolam 
among the pediatric and adoloscents 
during dental procedure, the most 
common effect was paradoxical 
reaction, including aggressiveness. 
 There were five side effects which 
were encountered during the study 
and these were excessive somnolence, 
hypotension, headache, vomiting and 
allergy. However, none of them were 
life-threatening i.e. coma, respiratory 
arrest or cardiovascular effects. This 
study was comparable to the study by 
which reported no serious respiratory 
or cardiovascular events while using 
midazolam intravenously (Ramoska et 
al. 1991; Wenzel et al. 2002; Xing et al. 
2013). Our study is similar to a previous 
study which included intravenous 
midazolam used for critical patients 
such as head injury, sepsis, meningitis 
and all types of drug combinations, 
which is sedative in nature (propofol 
and opioids) (Ramoska et al. 1991). 
Other neurological effects such as 
euphoria, aggressiveness, depression 
and intense hiccups were not 
documented in the clinical case notes, 
neither it was undetected nor classified 
as somnolence. As comparison 
to a study by Wenzel et al. (2002) 
neuropsychiatric effects including 
aggressive, euphoria and depressive 
behaviors made up to 6% of cardiac 
cases undergoing transesophageal 
echocardiography. 
 There were 6 (1.6%) cases reported 
on excessive somnolence involving 
midazolam alone and 4 (1.1%) cases 
reported with drug combination, 
which accounts to 10 cases (3.8%). 
Majority of excessive somnolence is 
due to repeated dosage given due to 
inadequate sedation from the initial 
dose. A 41-year-old male with clavicle 
and rib fracture was reported to have 
received total of 8 mg IV midazolam. 
The additional dosage was given due to 
his agitation at that time. He developed 
somnolence with duration of 2 hours 
with GCS 11/15. He was monitored 
later and did not develop respiratory or 
cardiovascular effects. The frequency is 
slightly higher than what was reported 
by (Ramoska et al. 1991) in which 
excessive somnolence was observed in 
(1.6%) of 120 patients.
 The second side effect was 6 
(1.6%) cases of drug hypersensitivity 
reaction. Two (1.1%) patients resulted 
dermatology effects with midazolam 
alone. Both cases developed itch and 
urticarial rash at a range of 1-2 hours 
after midazolam administration. The 
other 4 cases were in combination 
with other drugs i.e. opiates, hence 
cannot eliminate the combination 
or histamine release by opiods. The 
patient was stable afterwards after 
administration of hydrocortisone and 
piriton. Life-threatening laryngospasm 
or anaphylactic shock did not develop 
during the period of our study. 
 Hypotension was recorded in 7 (1.8%) 
cases. Patients with hypertension were 
found to have higher risk of developing 
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hypotension with the administration 
of midazolam, which correlates with 
previous studies (Shekerdemian 
et al. 1997). Hypotension after 
midazolam administration was due to 
cardiovascular depressant effect that 
results in minimal change in arterial 
blood pressure, heart rate and systemic 
vascular resistance (Shekerdemian et 
al. 1997). Other contributing factors 
to hypotension were co-morbidity, 
other combination of drugs given and 
underlying illnesses. Another case 
reported was a 87-year-female who had 
hypertension, chronic kidney disease 
and complete heart block. She was 
given a 1.5 mg midazolam and 0.5 mg 
fentanyl for sedation. She developed 
hypotension which her blood pressure 
falls from 191/61 mmHg to 96/35 
mmHg with heart rate of 36 beats per 
min after 4 hrs. Temporary pacemaker 
was inserted and later blood pressure 
was stabilized. In this case, hypotension 
developed might be due to several 
factors such as elderly age which affect 
the renal clearance and her clinical 
conditions like bradycardia and heart 
block. All cases of hypotension which 
developed post intravenous midazolam 
administration were transient and 
resolved with supportive measures.
 Three (0.8%) patients developed 
vomiting. This is lower than previous 
reports (2-3%) (American Hospital 
Formulary Service 1989). Three (0.8%) 
patients developed headache post 
midazolam administration which 
then resolved. Adverse effects will be 
considered severe or life-threatening if 
it results in permanent organ damage 
or death. Adverse effects that are 
selected in this category are cardiac 
arrest, apnoea, anaphylaxis and severe 
respiratory depression which resultes 
in hypoxia and neurological sequelae. 
Papineni et al. (2014) classified life- 
threatening as prolonged respiratory 
depression and hypoxia. No case was 
reported with such serious side effects. 
 A limitation of this study was the 
retrospective data collection. We 
could not obtain all the medical files 
requested in a short duration. Few of 
the medical records provided were 
incomplete and inconsistent as there 
were no proper documentations of 
certain side effects from the files. Not 
all adverse effects were documented 
and are most neuropsychiatric effects 
were labeled under the group of 
altered mental state, or low GCS, 
whereas it could mean euphoria, 
aggressiveness or somnolence. It was 
also impossible to compare when 
drugs used in combination, whether 
the effects were due to midazolam 
alone, or confounding effect with other 
drugs. There was no significant result. 
This study was more towards a role of 
an audit, in which the adverse effects 
of midazolam in our ED did not differ 
much from the general population.   
CONCLUSION
Statistical values showed that there 
was no significant association with 
the demographic factors and the 
drugs combination towards the side 
effects of midazolam use in ED. No 
life-threatening side effects occured 
following the use of midazolam, in 
consideration of the wide variety of 
critical patients. Thus, we conclude 
that midazolam is a very safe drug used 
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in ED. In fact, special caution, close 
monitoring and precaution steps should 
be carried out during the administration 
of midazolam in ED. We should 
follow the guideline of management 
recommended in ED so that the usage 
of midazolam can be optimized with 
minimal side effects in clinical setting. 
Caution should be practiced in elderly. 
In addition, as in advent to introduction 
of new sedative agent such as propofol 
and etomidate, the role of midazolam is 
still considered to be safe.
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